SUNNYVALE, Calif.—Samath Jamie, Executive Vice President and Chief Financial Officer of Intuitive Surgical Inc . (NASDAQ:ISRG), recently executed a series of stock transactions, including selling shares valued at $158,710. The transactions, reported on February 10, involved multiple dealings in common stock of the $212 billion medical technology company. According to InvestingPro data, ISRG currently trades near its 52-week high, having delivered an impressive 53% return over the past year.
Jamie sold 269 shares of Intuitive Surgical at a price of $590.00 per share, totaling $158,710. The sales were part of a pre-arranged trading plan compliant with SEC Rule 10b5-1, set to expire on May 6, 2025. The company maintains a strong financial position, with InvestingPro analysis indicating a "GREAT" overall financial health score.
In addition to the sales, Jamie acquired shares through various transactions. The acquisitions included 269 shares at prices ranging from $229.39 to $304.67, totaling $71,793. These acquisitions were primarily through the exercise of stock options and restricted stock units (RSUs).
Following these transactions, Jamie’s direct ownership stands at 3,282 shares. The transactions reflect a combination of strategic sales and acquisitions, aligning with Jamie’s ongoing engagement with Intuitive Surgical.
In other recent news, Intuitive Surgical has been the focus of multiple analyst firms following a strong fourth-quarter performance in 2024. RBC Capital Markets maintained an Outperform rating with a $641 price target, highlighting the company’s 10% and 24% beat on revenue and earnings per share (EPS), respectively. Piper Sandler increased the price target to $670, noting the company’s exceeded consensus expectations for both revenue and earnings.
Oppenheimer maintained a Perform rating, pointing out the company’s impressive Q4 results, but expressed caution due to the nearing saturation of the U.S. market for Intuitive Surgical’s products. Bernstein analysts reiterated an Outperform rating and a price target of $700, emphasizing the company’s potential for consistent improvement in financial metrics throughout 2025.
Lastly, Truist Securities updated its price target to $666, maintaining a Buy rating despite anticipated headwinds such as a decline in gross margins and a forecasted currency exchange revenue impact. These recent developments offer insights into the current market perspective on Intuitive Surgical, as the company continues to surpass expectations and prepare for the launch of its next-generation surgical system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.